Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04801043 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.
A Phase 1 study, sponsored by Evopoint Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04801043 is a Phase 1 study that has completed, run by Evopoint Biosciences. The registered enrollment target is 24 participants.
The verdict
NCT04801043, a Phase 1 study, has completed, sponsored by Evopoint Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-min (± 3 min) IV infusion in healthy adult young females and in healthy adult elderly males and females.
Interventions
- DRUG placebo
- DRUG XNW4107
- DRUG Imipenem/Cilastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04801043
The ClinicalTrials.gov registry entry for NCT04801043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evopoint Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT04801043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04801043 about?
NCT04801043 is a clinical study titled "To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.". This is a Phase 1, randomized, double-blind, placebo-controlled study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-min (± 3 min) IV infusion in healthy adult young females and in healthy adult elderly males and females.
What is the current status of trial NCT04801043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-03-02. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04801043?
The interventions under investigation include: placebo (DRUG), XNW4107 (DRUG), Imipenem/Cilastatin (DRUG).
Who is sponsoring clinical trial NCT04801043?
This trial is sponsored by Evopoint Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.